

Company Overview

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington's disease and myotonic dystrophy, as well as a variety of other genetic disorders.

NeuBase Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference

Apr 27 2021, 8:00 AM EDT

NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 26 2021, 4:01 PM EDT

NeuBase Therapeutics Announces Pricing of \$40 Million Public Offering of Common Stock

Apr 22 2021, 9:07 AM EDT

Stock Overview

Symbol NBSE
Exchange Nasdaq
Market Cap 170.64m
Last Price \$5.27
52-Week Range \$5.02 - \$12.90

05/07/2021 04:00 PM EDT

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-535-7746
daniel@lifesciadvisors.com

Management Team

Dietrich A. Stephan, Ph.D.

Chairman & Chief Executive Officer, Founder

Robert Friedlander, M.D.

Consulting Chief Medical Officer

Sam Backenroth

Chief Financial Officer and SVP of Business Development

Curt Bradshaw, Ph.D.

Chief Scientific Officer

William Mann, Ph.D.

Chief Operating Officer

Robert Zamboni, Ph.D.

Chief of Preclinical Development

NeuBase Therapeutics, Inc.

700 Technology Drive
Pittsburgh, PA 15219

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.